Phenotypes associated with this allele
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Prkcshtm1Som mutation
(0 available);
any
Prkcsh mutation
(27 available)
Tg(CAG-cre/Esr1*)1Lbe mutation
(0 available)
|
|
|
mortality/aging
|
|
• in mice treated with a high does tamoxifen induction regime
|
liver/biliary system
|
|
• bile duct-derived cysts in the liver beginning at P28 in tamoxifen-treated mice
• severe by 4 to 5 months in tamoxifen-treated mice
• expression of Tg(Pkd2)#Som expression does not rescue cystic liver phenotype
• however, expression of Tg(Pdk1)248Som rescues cystic liver phenotype
|
growth/size/body
|
|
• bile duct-derived cysts in the liver beginning at P28 in tamoxifen-treated mice
• severe by 4 to 5 months in tamoxifen-treated mice
• expression of Tg(Pkd2)#Som expression does not rescue cystic liver phenotype
• however, expression of Tg(Pdk1)248Som rescues cystic liver phenotype
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Sec63tm1Som mutation
(0 available);
any
Sec63 mutation
(40 available)
Tg(CAG-cre/Esr1*)1Lbe mutation
(0 available)
|
|
|
mortality/aging
|
|
• in mice treated with a high does tamoxifen induction regime
|
liver/biliary system
|
|
• bile duct-derived cysts in the liver beginning at P28 in tamoxifen-treated mice
• severe by 4 to 5 months in tamoxifen-treated mice
• expression of Tg(Pkd2)#Som expression does not rescue cystic liver phenotype
• however, expression of Tg(Pdk1)248Som rescues cystic liver phenotype
|
growth/size/body
|
|
• bile duct-derived cysts in the liver beginning at P28 in tamoxifen-treated mice
• severe by 4 to 5 months in tamoxifen-treated mice
• expression of Tg(Pkd2)#Som expression does not rescue cystic liver phenotype
• however, expression of Tg(Pdk1)248Som rescues cystic liver phenotype
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Memo1tm1.1Neh mutation
(0 available);
any
Memo1 mutation
(47 available)
Tg(CAG-cre/Esr1*)1Lbe mutation
(0 available)
|
|
|
mortality/aging
|
|
• in tamoxifen-treated mice
|
reproductive system
 |
• in tamoxifen-treated mice
|
|
|
• small gonads in some litters of tamoxifen-treated mice
|
homeostasis/metabolism
growth/size/body
|
|
• in tamoxifen-treated mice
|
|
|
• in tamoxifen-treated mice
|
|
|
• in tamoxifen-treated mice
|
integument
|
|
• in tamoxifen-treated mice
|
|
|
• greying hair in tamoxifen-treated mice
|
|
|
• in tamoxifen-treated mice
|
adipose tissue
|
|
• in tamoxifen-treated mice
|
|
|
• in tamoxifen-treated mice
|
skeleton
|
|
• in tamoxifen-treated mice
|
behavior/neurological
|
|
• abnormal hindlimb reflex in tamoxifen-treated mice
|
pigmentation
|
|
• greying hair in tamoxifen-treated mice
|
endocrine/exocrine glands
|
|
• small gonads in some litters of tamoxifen-treated mice
|
cellular
|
|
• in tamoxifen-treated mice
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Shank3tm5.1Gfng mutation
(1 available);
any
Shank3 mutation
(77 available)
Tg(CAG-cre/Esr1*)1Lbe mutation
(0 available)
|
|
|
behavior/neurological
|
|
• prior to tamoxifen administration, mice exhibit decreased total distance travelled in open field test as compared to controls
• following tamoxifen administration, phenotype is unchanged
|
|
|
• prior to tamoxifen administration, mice spend less time in open arm during elevated zero maze test as compared to controls
• following tamoxifen administration at P20-21, mice exhibit reduced anxiety in the maze test
• tamoxifen administration in adult mice results in an unchanged phenotype
|
|
|
• prior to tamoxifen administration, mice exhibit repetitive grooming
• following tamoxifen administration, grooming is similar to control
|
|
|
• prior to tamoxifen administration, mice exhibit decreased latency to fall in rotarod test as compared to controls
• following tamoxifen administration at P20-21, mice perform significantly better on rotarod
• tamoxifen administration in adult mice results in an unchanged phenotype
|
|
|
• prior to tamoxifen administration, mice exhibit reduced rearing time and frequency as compared to controls
• following tamoxifen administration, phenotype is unchanged
|
|
|
• prior to tamoxifen administration, mice exhibit no preference for a stranger mouse or novel object in a test of voluntary social interaction
• following tamoxifen administration, mice exhibit a preference for a stranger mouse over a novel object in a test of voluntary social interaction
|
growth/size/body
|
|
• as compared to wild-type mice (no tamoxifen administered)
|
nervous system
|
|
• prior to tamoxifen administration, mice exhibit a reduction of spine density in medium spiny neurons as compared to controls
• following tamoxifen administration, spine density is increased to a greater density than controls
|
|
|
• prior to tamoxifen administration, mice exhibit a reduction of spine density in medium spiny neurons
• following tamoxifen administration, spine density is increased to a greater density than controls
|
|
|
• prior to tamoxifen administration, mice exhibit a reduced field population spikes in the dorsal striatum as compared to controls
• following tamoxifen administration, mice exhibit field responses similar to control
|
|
|
• prior to tamoxifen administration, mice exhibit a reduced mEPSC frequency as compared to controls
• following tamoxifen administration, mice exhibit mEPSC frequencies similar to control
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Flcntm1.1Lss mutation
(0 available);
any
Flcn mutation
(40 available)
Flcntm1Baba mutation
(0 available);
any
Flcn mutation
(40 available)
Tg(CAG-cre/Esr1*)1Lbe mutation
(0 available)
|
|
|
immune system
|
|
• pro-B cell block in the bone marrow following tamoxifen-treatment
|
|
|
• CD19+ cells in the spleen following tamoxifen-treatment
|
renal/urinary system
|
|
• in tamoxifen-treated mice
• in tamoxifen-treated mice however, kidney phenotype is rescued by rapamycin treatment
|
|
|
• in tamoxifen-treated mice
• however, kidney phenotype is rescued by rapamycin treatment
|
hematopoietic system
|
|
• pro-B cell block in the bone marrow following tamoxifen-treatment
|
|
|
• CD19+ cells in the spleen following tamoxifen-treatment
|
growth/size/body
|
|
• in tamoxifen-treated mice
• in tamoxifen-treated mice however, kidney phenotype is rescued by rapamycin treatment
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(CAG-cre/Esr1*)1Lbe mutation
(0 available)
Vhltm1.1Lss mutation
(0 available);
any
Vhl mutation
(16 available)
Vhltm1Lss mutation
(0 available);
any
Vhl mutation
(16 available)
|
|
|
mortality/aging
|
|
• all embryos of pregnant females injected with 2 mg of tamoxifen at E10.5 to inactive Vhlh during mid-gestational stage, die between E14.5 and E15.5
|
growth/size/body
|
|
• embryos of pregnant females injected with tamoxifen at E10.5 are smaller than controls
|
cardiovascular system
|
|
• treatment of pregnant females at E10.5 with tamoxifen results in abnormal vasculature and dilated blood vessels in the body of E14.7 embryos
|
|
|
• dilated vessels are frequently seen after tamoxifen treatment
|
|
|
• treatment of pregnant females at E10.5 with tamoxifen results in impaired blood circulation in the yolk sac of E14.7 embryos
|
|
|
• treatment of pregnant females at E10.5 with tamoxifen results in hemorrhage in the dorsolateral region of embryos at E14.5
|
cellular
|
|
• at 24 hrs after bilateral renal ischemia-reperfusion injury (IRI), tamoxifen-treated mice exhibit significantly fewer TUNEL+ cells in the proximal tubules relative to tamoxifen-treated control mice
|
|
|
• treatment of pregnant females at E10.5 with tamoxifen results in extensive embryo necrosis
|
|
|
• treatment of pregnant females at E10.5 with tamoxifen results in focal necrosis in the liver or E14.5 embryos
|
embryo
|
|
• treatment of pregnant females at E10.5 with tamoxifen results in impaired blood circulation in the yolk sac of E14.7 embryos
|
|
|
• treatment of pregnant females at E10.5 with tamoxifen results in extensive embryo necrosis
|
|
|
• embryos of pregnant females injected with tamoxifen at E10.5 are smaller than controls
|
|
|
• when pregnant females are injected with tamoxifen at E10.5, frequently observe dilated blood vessels and spongiotriophoblast cells in the labyrinthine layer
|
|
|
• dilated vessels are frequently seen after tamoxifen treatment
|
|
|
• thickness of the labyrinthine layer is reduced when pregnant females are injected with tamoxifen at E10.5
|
liver/biliary system
|
|
• treatment of pregnant females at E10.5 with tamoxifen results in focal necrosis in the liver or E14.5 embryos
|
integument
|
|
• seen in embryos of pregnant females injected with tamoxifen at E10.5
|
homeostasis/metabolism
renal/urinary system
|
|
• at 24 hrs after bilateral renal ischemia-reperfusion injury (IRI), tamoxifen-treated mice exhibit significantly fewer TUNEL+ cells in the proximal tubules relative to tamoxifen-treated control mice
|
|
|
• at 24 hrs after bilateral renal IRI, tamoxifen-treated mice (0.36mg/g body weight injected i.p. one wk prior to IRI) exhibit better preservation of renal function and significantly lower tubular injury scores than tamoxifen-treated control mice (2.40 +/- 0.08 and 0.90 +/- 0.12, respectively), consistent with reduced proximal tubular injury, near absence of TUNEL+ cells, and milder tubular epithelial degeneration
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Sirpatm1Umri mutation
(0 available);
any
Sirpa mutation
(50 available)
Tg(CAG-cre/Esr1*)1Lbe mutation
(0 available)
|
|
|
nervous system
|
|
• as determined by VGLUT1 (Slc17a7) staining, mice treated with tamoxifen at P15 exhibit impaired maturation of presynaptic terminals compared with control mice
• however, mice treated tamoxifen at P0 exhibit normal initial synapse development and mice treated at P30 exhibit normal synapse maintenance
|
|
|
• irregular shape in tamoxifen-treated mice
|
|
|
• tamoxifen treated mice exhibit fewer synaptic vesicles and fewer docked synaptic vesicles in asymmetric synapses compared with control mice
|
|
|
• strongly diminished Input-output curves of field excitatory postsynaptic potential slope in tamoxifen-treated mice
• however, fiber volley amplitude is normal
|
|
|
• in tamoxifen-treated mice
|
|
|
• in tamoxifen-treated mice
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Chattm1Jrs mutation
(1 available);
any
Chat mutation
(57 available)
Tg(CAG-cre/Esr1*)1Lbe mutation
(0 available)
|
|
|
mortality/aging
|
|
• mutant mice die by P14 - P15 following treatment with 100 ug of tamoxifen on P0 which results in excision of the floxed sequence in greater than 50% of motor neurons
|
nervous system
|
|
• following a low dose of tamoxifen (5 ug) on P0, which results in excision of the floxed sequence in 10-20% of motor neurons, an increase in doubly innervated neuromuscular junctions is seen
• in these doubly innervated neuromuscular junctions when a non-excised axon is present it is significantly larger than the excised axon
|
behavior/neurological
|
|
• mutant mice become noticeably weak by P9 following treatment with 100 ug of tamoxifen on P0
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Chattm1Jrs mutation
(1 available);
any
Chat mutation
(57 available)
Tg(CAG-cre/Esr1*)1Lbe mutation
(0 available)
|
|
|
mortality/aging
|
|
• when receiving a high dose of tamoxifen at P0, mice display weakness at P9 and die at P14-15
|
nervous system
|
|
• at synapses innervated by a Chat +ve and a Chat -ve axons, the pre-terminal caliber of the Chat +ve axon is usually greater and never less than the Chat -ve diameter; average axon diameter at synapses with two Chat -ve or 2 Chat +ve axons are similar
• at synapses innervated by 2 Chat +ve axons, average diameter is less than the Chat +ve axon innervating a synapse also innervated by a Chat -ve axon; average diameter of axons at Chat -ve dually innervated synapses is greater than diameter of Chat -ve axon at a synapse also innervated by a Chat +ve axon
• these results suggest that activity differences between axons (Chat +ve - active, normal vs Chat -ve - inactive) determine size of axon branches at NMJs
|
|
|
• at NMJs that are doubly innervated by 1 Chat +ve and 1 Chat -ve axon, the Chat-positive axon occupies more than half of the total area occupied by both axons together (~85%); this is the case with both high and low doses of tamoxifen
• in high dose tamoxifen NMJs, this pattern is observed even though the majority of axons are Chat -ve, indicating that the greater area occupied by Chat +ve axons is not the result of a bias of higher Chat +ve axon numbers
• in NMJs innervated singly or doubly by Chat -ve axons, the axons fully occupy the synaptic sites, indicating that Chat -ve axons do not withdraw from synapses
|
behavior/neurological
|
|
• after a high dose of tamoxifen administered after birth (P0), mice become noticeably weaker than nontransgenic littermates
|
Analysis Tools